申请人:Glaxo Group Limited
公开号:US05109008A1
公开(公告)日:1992-04-28
Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents hydrogen, unsubstituted or substituted C.sub.1-6 alkyl, halogen, --COR.sub.4 or --CO.sub.2 R.sub.4 (where R.sub.4 represents hydrogen or unsubstituted or substituted C.sub.1-6 alkyl); R.sub.2 and R.sub.3 are the same or different and are C.sub.1-6 alkyl or C.sub.3-6 alkenyl; or --NR.sub.2 R.sub.3 forms a 5-membered (optionally containing an oxygen atom adjacent to the nitrogen) or a 6-membered ring, which ring optionally contains one unit of unsaturation and which is unsubstituted or substituted by hydroxy, C.sub.1-6 acyloxy, oxo, optionally substituted methylidene, --COR.sub.5 (where R.sub.5 represents C.sub.1-6 alkyl, OR.sub.6 or --NHR.sub.6, and R.sub.6 represents hydrogen, C.sub.1-6 alkyl, aryl or ar(C.sub.1-6)alkyl) or said ring is substituted by .dbd.NOR.sub.7 (where R.sub.7 represents C.sub.1-6 alkyl); Z represents --O-- or --S--; X represents a direct bond, --CH.sub.2 -- or --CH.sub.2 O--; Ar represents a substituted phenyl moiety; and pharmaceutically acceptable salts thereof. The compounds are indicated as useful in the treatment of pain and cerebral ischaemia. Processes and intermediates for their preparation and pharmaceutical compositions containing them are also disclosed.
公开了式(I)的化合物
其中,R.sub.1代表氢,未取代或取代的C.sub.1-6烷基,卤素,-COR.sub.4或-CO.sub.2R.sub.4(其中R.sub.4代表氢或未取代或取代的C.sub.1-6烷基); R.sub.2和R.sub.3相同或不同,是C.sub.1-6烷基或C.sub.3-6烯基; 或-NR.sub.2R.sub.3形成一个5-成员环(可选地包含与氮相邻的氧原子)或6-成员环,该环可选地含有一个不饱和单元,未取代或取代的羟基,C.sub.1-6酰氧基,氧代,可选地取代的甲基亚甲基,-COR.sub.5(其中R.sub.5代表C.sub.1-6烷基,OR.sub.6或-NHR.sub.6,R.sub.6代表氢,C.sub.1-6烷基,芳基或芳基(C.sub.1-6)烷基)或所述环被.dbd.NOR.sub.7(其中R.sub.7代表C.sub.1-6烷基)取代; Z代表-O-或-S-; X代表直接键,-CH.sub.2-或-CH.sub.2O-; Ar代表取代的苯基基团;以及其药物可接受的盐。这些化合物被指示为治疗疼痛和脑缺血的有用药物。还公开了它们的制备过程和中间体以及含有它们的制药组合物。